Sunzen Biotech Berhad (KLSE: SUNZEN)

Sunzen Biotech Berhad Balance Sheet

Financials in millions MYR. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	27.04	27.04	18.66	11.67	46.67	38.39
Short-Term Investments	0.56	0.56	4.32	0.45	0.88	0.45
Cash & Short-Term Investments	27.6	27.6	22.98	12.13	47.55	38.84
Cash Growth	70.02%	20.11%	89.47%	-74.49%	22.42%	16.85%
Accounts Receivable	14.79	14.79	19.5	20.41	12.52	7.53
Other Receivables	2.27	2.27	4.69	0.36	0.63	1.56
Receivables	17.06	17.06	24.19	20.76	13.15	9.08
Inventory	9.47	9.47	8.55	11.33	13.98	12.27
Prepaid Expenses	1.54	1.54	-	0.47	0.19	0.55
Restricted Cash	0.59	0.59	-	0.56	0.55	0.54
Other Current Assets	0.87	0.87	-	0.15	0.81	14.44
Total Current Assets	57.13	57.13	55.72	45.41	76.22	75.72
Property, Plant & Equipment	55.38	55.38	45.87	46.81	47.82	47.42
Long-Term Investments	0.56	0.56	0.79	-	-	-
Goodwill	2.85	2.85	2.85	2.85	2.85	-
Other Intangible Assets	-	-	-	-	0.03	0.07
Long-Term Accounts Receivable	53.9	53.9	52.9	55.39	21.78	-
Other Long-Term Assets	0.5	0.5	0.5	0.5	-	-
Total Assets	170.32	170.32	158.63	150.96	148.71	123.2
Accounts Payable	3.94	3.94	5.99	9.2	9.58	5.67
Accrued Expenses	2.05	2.05	-	2.09	2.33	1.94
Current Portion of Long-Term Debt	0.29	0.29	0.32	0.13	0.13	10.01
Current Portion of Leases	0.38	0.38	0.46	0.26	0.37	0.2
Current Income Taxes Payable	0.16	0.16	0.5	0.24	0.49	0.01
Current Unearned Revenue	0.13	0.13	-	0.37	0.85	2.56
Other Current Liabilities	1.07	1.07	2.68	0.58	0.87	0.87
Total Current Liabilities	8.04	8.04	9.94	12.87	14.61	21.27
Long-Term Debt	6.2	6.2	6.34	4.49	4.61	4.74
Long-Term Leases	0.8	0.8	0.72	0.26	0.47	0.5
Long-Term Deferred Tax Liabilities	5.46	5.46	3.59	3.57	3.55	3.22
Other Long-Term Liabilities	-	-	0.06	0.05	-	-
Total Liabilities	20.49	20.49	20.65	21.25	23.24	29.72
Common Stock	111.84	111.84	110.29	110.22	108.18	76.52
Retained Earnings	9.2	9.2	6.96	-0.27	-4.08	-15.66
Treasury Stock	-2.96	-2.96	-2.96	-2.96	-0.96	-0.96
Comprehensive Income & Other	21.31	21.31	14.43	14.89	14.95	27.57
Total Common Equity	139.39	139.39	128.72	121.88	118.1	87.47
Minority Interest	10.44	10.44	9.26	7.83	7.37	6.01
Shareholders' Equity	149.84	149.84	137.98	129.71	125.47	93.48
Total Liabilities & Equity	170.32	170.32	158.63	150.96	148.71	123.2
Total Debt	7.66	7.66	7.83	5.14	5.59	15.45
Net Cash (Debt)	19.94	19.94	15.15	6.98	41.96	23.4
Net Cash Growth	79.54%	31.61%	116.90%	-83.36%	79.36%	40.67%
Net Cash Per Share	0.02	0.02	0.02	0.01	0.07	0.04
Filing Date Shares Outstanding	712.53	712.53	704.86	704.74	708.16	530.96
Total Common Shares Outstanding	712.54	712.54	704.86	704.6	705.82	528.76
Working Capital	49.09	49.09	45.77	32.54	61.61	54.45
Book Value Per Share	0.20	0.20	0.18	0.17	0.17	0.17
Tangible Book Value	136.54	136.54	125.87	119.03	115.22	87.41
Tangible Book Value Per Share	0.19	0.19	0.18	0.17	0.16	0.17
Land	27.09	27.09	-	23.12	23.12	23.12
Buildings	23.63	23.63	-	20.25	20.18	19.1
Machinery	21.86	21.86	-	23.21	24.3	22.33
Construction In Progress	-	-	-	-	0.12	0.35
Leasehold Improvements	-	-	-	-	-	0.23

Source: S&P Capital IQ. Standard template. Financial Sources.